[ topical analysis ] propaganda analysis
Japan to seek criminal prosecution of Novartis Japan to seek criminal prosecution of Novartis
* December 18, 2013
Japan to seek criminal prosecution of Novartis
Japan's health ministry intends to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged fabrication of drugs data, a report said Wednesday.
Novartis Pharma KK has been under fire since a university said the data might have been skewed to promote a popular blood-pressure drug.
Health Minister Norihisa Tamura has characterised as "extremely regrettable" the incident in which an employee of the world's number two drug maker hid his affiliation during a medical study into the effects of Valsartan.
The ministry, which has since investigated the case, is now planning to file a criminal complaint seeking punishment not only for the company but also for individuals involved in the scandal, the Yomiuri Shimbun reported.
A ministry official in charge of the issue told AFP no firm decision had yet been made.
Under Japan's pharmaceutical law, anyone found guilty of exaggerated advertising can be punished with up to two years' prison or a fine of as much as two million yen ($19,400).
A ministry panel of experts concluded in September that Novartis Pharma KK should be held responsible for studies at various universities that used manipulated data on the drug.
The studies suggested the drug -- sold under the name Diovan in Japan and licensed for use in more than 100 countries -- had some prophylactic effect on strokes and angina.
The firm used data from the studies to market its drug, playing up its supposed additional benefits.
Novartis has maintained that the company had no knowledge of the wrongdoing, in which an ex-employee allegedly failed to disclose his affiliation with Novartis during various academic studies in which incomplete clinical data were used.
The worker and other researchers involved in studies have denied to the panel that they manipulated the data.
In September Novartis Pharmaceuticals chief David Epstein was called to meet with the health minister and promised to cooperate with Tokyo's probe into the matter.
Epstein apologised for the concern the incident has caused, but did not admit the company's role in the allegations.
Tokyo's Jikei University School of Medicine has retracted research that appeared in respected medical journal The Lancet six years ago due to data fabrication.
Kyoto Prefectural University of Medicine also concluded that its studies on the drug used incomplete clinical data.
Chiba University said Tuesday it could not find intentional data fabrication but researchers failed to disclose 91 million yen ($880,000) in scholarship donations from the pharmaceutical company in the three years from 2007 to 2009.
Explore further: Japan to raid Novartis over alleged data fabrication: reports
Journal reference: The Lancet
* Most shared
Lack of preciousss vitamin made Gollum a loser
Dec 15, 2013 7
The brain's data compression mechanisms: Neurons subtract images and use the differences
17 hours ago 4
Team grows kidney from stem cells
Dec 16, 2013 2
World's smallest Medtronic Micra pacemaker: Cardiac pacing game change?
Dec 15, 2013 2
Do vitamins block disease? Some disappointing news
Dec 16, 2013 12
Medical Xpress on facebook
* Send Feedback
Japan to raid Novartis over alleged data fabrication: reports Sep 27, 2013
Japanese authorities are preparing to raid the local arm of Swiss pharmaceutical giant Novartis over data fabrication claims, reports said Friday.
Japan university reveals more claims of fabricated drug data Jul 31, 2013
A Japanese university Wednesday said it would retract a study that touted the effectiveness of a blood pressure drug made by Swiss pharmaceutical giant Novartis because it was based on fabricated data.
Swiss pharma Novartis ups full-year sales outlook (Update) Oct 22, 2013
Swiss pharmaceutical giant Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan, even though it said negative currency trends ...
Novartis to cut more than 440 jobs in Britain Nov 06, 2013
Swiss pharmaceuticals giant Novartis said Wednesday it aimed to slash more than 440 jobs in Britain, blaming industry-wide difficulties.
Roche 'extremely open' to talks with Novartis: report Oct 01, 2013
The head of Swiss pharmaceutical giant Roche is open to renewed cooperation with competitor Novartis, he told the Financial Times in an interview published Tuesday.
Recommended for you
Pfizer, Teva reach deal to allow generic Viagra 13 hours ago
Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.
GSK to scrap individual sales targets (Update) 22 hours ago
British drug company GlaxoSmithKline said Tuesday it would stop paying doctors to promote its products at speaking engagements and scrap individual sales targets, months after its ethics were challenged by a bribery scandal ...
New concerns over safety of common anesthetic Dec 13, 2013
Patients receiving the widely used anesthesia drug etomidate for surgery may be at increased risk or mortality and cardiovascular events, according to a study in the December issue of Anesthesia & Analgesia, official journa ...
Experimental diabetes drug makes comeback Dec 12, 2013
A panel of federal health advisers has backed the benefits of an experimental diabetes drug that uses a new method to reduce blood sugar, setting aside previous concerns about the pill's safety.
FDA approves first generic versions of Cymbalta Dec 11, 2013
The Food and Drug Administration says it has approved the first generic versions of the blockbuster antidepressant drug Cymbalta, offering lower-cost access to one of the most widely prescribed treatments for depression, ...
Brief laser-light treatment may significantly improve effectiveness of influenza vaccines Dec 11, 2013
Pretreating the site of intradermal vaccination -- vaccine delivered into the skin rather than to muscles beneath the skin -- with a particular wavelength of laser light may substantially improve vaccine effectiveness without ...
|re:0.17 st:0.01 fo:0 s:0 d:1.05 c:0 db:0.14 a:0.34 m:0.22 t:2.27 (f)|
text of article used for CRITICAL ANALYSIS, under FAIR USE provisions of the Copyright Act of 1976, 17 U.S.C. § 107, et al.